Volume 03 Issue 04-2023
129
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
the Andijan regional oncology dispensary analyzed the 120 patients on the "D" account for the side effects observed
after chemotherapy and chronochemotherapy treatments. In 80-90% of patients receiving chemotherapy, different
manifestations of side effects are observed. The observation of these toxic complications is explained by the effect of
the cytostatic drug on typical cells.
KEYWORDS
Chemotherapy, chronochemotherapy, toxic complications.
INTRODUCTION
Research Article
ASSESSMENT OF TOXIC COMPLICATIONS OF CHRONOCHEMOTHERAPY
IN THE TREATMENT OF MALIGNANT TUMOR DISEASES
Submission Date:
April 20, 2023,
Accepted Date:
April 25, 2023,
Published Date:
April 30, 2023
Crossref doi:
https://doi.org/10.37547/ijmscr/Volume03Issue04-21
Karimov M.A.
Namangan State University, Faculty Of Medicine, Uzbekistan, Namangan, Uzbekistan
Makhmudova R.Y.
Kosonsoy Abu Ali Ibn Sino Public Health Technical University, Namangan, Uzbekistan
Abduraimova R.A.
Kosonsoy Abu Ali Ibn Sino Public Health Technical University, Namangan, Uzbekistan
O'rinboev M.R.
Kosonsoy Abu Ali Ibn Sino Public Health Technical University, Namangan, Uzbekistan
Beknazarov A.T.
Kosonsoy Abu Ali Ibn Sino Public Health Technical University, Namangan, Uzbekistan
Nurkabilov O.T.
Kosonsoy Abu Ali Ibn Sino Public Health Technical University, Namangan, Uzbekistan
Journal
Website:
https://theusajournals.
com/index.php/ijmscr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 03 Issue 04-2023
130
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Improving the effectiveness of treatment and
preventive measures in modern medicine remains one
of the pressing problems of Medicine [17]. This can be
done by a chronobiological method in the conservative
treatment of patients in finding a future solution to the
problem [7, 9, 11, 13, 14].
There are several methods of treating malignant tumor
diseases, within which treatment with cytostatic drugs
is widely used. In chemotherapy, the therapeutic result
is always manifested along with a number of side
effects, and these conditions are explained by the
cytostatic effect of the cytostatic drug on the
malignant tumor cell in the oranism and the cytostatic
effect on the normal cell. In 80-90% of patients,
different manifestations of side effects are observed
after chemotherapy [18].
Currently, it has been found that a huge number of
physiological processes that are carried out in the
human div change during the day [10, 17, 21], but in
the literature we studied, the data on the use of
cytostatic drugs in oncology based on biological
rhythms has been little studied.
The first to record in science was the English writer
John Wren in 1632 in his work "Herbal Treatise", which
records daily rhythms [3]. By the end of the XIX
century, the science of daily rhythms began to be used
in science, such as biorhythmology, the administration
of drugs to the div based on daily rhythms, and the
study of pharmacokinetics and pharmacodynamics of
the drug
–
chronopharmacology, the treatment based
on daily rhythms-chronotherapy.
In recent years, chronopharmacology has been studied
in all areas of Medicine [4], but the literature has
provided very little data on chemotherapy based on
daily rhythms in the treatment of oncological diseases.
Chronochemotherapy is a section of chronotibbiot
aimed
at
increasing
the
effectiveness
of
chemiopreparate and reducing its side effects, using
cytostatic drugs based on the daily rhythm (circadian)
[1, 2]. Chronochemotherapy increases the cytostatic
effect of chemiopreparations and reduces the side
effects, complications of the drug [12, 15].
Chemotherapy based on biorhythms in oncology has
been shown to prolong the survival of patients by 2
times, increase the effectiveness of treatment by 1.5-2
times, and reduce poisoning by the div[5, 8, 20, 21].
The data presented in the literature indicate that in
typical (normal) cells according to biological rhythm,
the metabolism of substances actively occurs during
the day, while in the evening, on the contrary, the
metabolism slows down [16]. The exchange of
substances occurs equally actively at all times of the
day, bypassing the law of the cancer cell (atypical cell)
biorhymt, and the mitotic cycle of the atypical cell
occurs precisely at night [19]. The literature reports
that different antiblastic effects were obtained when
the same dose of cytostatic drugs was used at different
times of the day and side effects were partially
reduced. This condition is explained by the fact that the
mitotic cycle of the atypical cell occurs at night [6, 20].
The purpose of the work: to diagnose toxic
complications based on chronopharmacology of
cytostatic drugs used in the treatment of malignant
tumor diseases.
Material and examination methods: 120 patients
treated during the period 2012
–
2022, who were
counted" D "in the Andijan regional oncology
dispensaries, were examined according to the"
standard for the treatment and examination of
malignant tumor diseases " and received ad'yuvant,
neoad'yuvant
or
symptomatic
chemotherapy
treatments.
Volume 03 Issue 04-2023
131
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
All patients were subjected to extended general blood
analysis, general urine analysis, biochemical blood
analysis
(bilirubin,
transaminase,
creatinine,
mochevina, nitrogen mochevina), UTT and ECG
examinations
before
treatment
with
the
chemotherapy method, and appropriate schemes
were selected in accordance with the treatment
standard of cytostatic drugs and performed in the
same way as traditional chemotherapy doses. General
blood and urine analyses were seen repeatedly after
chemotherapy treatments were completed. According
to the above nazology, MAYO, FOLFOX, HELOX
schemes, ver or er schemes in germ cancer, MAYO,
FOLFOX
–
4, HELOX schemes in colon cancer, PF
Scheme in sub-lingual area cancer, PF Scheme in
bacadaon neck cancer, CAF, CMF schemes in mammary
cancer were selected.
Table 1
Distribution of patients by groups with respect to the nosological and disease stage
№
Disease nazology
group
n
Stage of the disease
II
III
IV
n
%
n
%
n
%
1
Colon cancer
I
20
0
0
15
75,0
5
25,0
II
17
2
11,8
11
64,7
4
23,5
2
Rectal cancer
I
18
0
0
12
66,7
6
33,3
II
15
3
20,0
8
53,3
4
26,7
3
Cervical cancer
I
2
0
0
0
0
2
100,0
II
14
2
14,3
7
50,0
5
35,7
4
Germ cancer
I
11
2
18,2
7
63,6
2
18,2
II
9
3
33,3
4
44,4
2
22,2
5
Ovarian cancer
I
0
0
0
0
0
0
0
II
5
0
0
3
60,0
2
40,0
6
Breast cancer
I
6
1
16,7
5
83,3
0
0
II
0
0
0
0
0
0
0
7
Pancreatic cancer
I
3
0
0
0
0
3
100,0
II
0
0
0
0
0
0
0
Total
I
60
3
5,0
39
65,0
18
30,0
II
60
10
16,7
33
55,0
17
28,3
Total
120
13
10,8
72
60,0
35
29,2
Group 1 consisted of 60 patients
–
"D" in the regional
oncology dispensaries and performed ad'yuvant,
neoad'yuvant
or
symptomatic
chemotherapy
treatments in the evening (at night). Chrono
chemotherapy procedures were performed on 20 (33.3
%), germ cancer
–
11 (18.3 %), colon cancer
–
18 (30 %),
breast cancer
–
6 (10 %), sub
–
lingual cancer
–
3 (5 %),
cervical cancer
–
2 (3.33 %) patients. Of the patients, 22
Volume 03 Issue 04-2023
132
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
(36.7 %) were female and 38 (63.3 %) were male. 3 (5 %)
of patients received treatment in Phase II, 39 (65 %)
received treatment in Phase III and 19 (10 %) received
treatment in Phase IV of the disease (Table 1).
Group 2-60 patients who are counted "D" in regional
oncology dispensaries have been examined and
undergo ad'yuvant, neoad'yuvant or symptomatic
chemotherapy treatments. In terms of the nosological
composition of the patients, 17 (28.3%) patients with
colon cancer
–
9 (15 %), colon cancer
–
15 (25 %), ovarian
cancer
–
5 (8.3 %), cervical cancer
–
14 (23.3 %) patients
underwent conventional chemotherapy. 27 of the
patients (45 %) were female and 33 (55%) were male. 3
(5%) of patients received treatment in Phase II, 39 (65
%) received treatment in Phase III and 19 (10 %) received
treatment in Phase IV of the disease (Table 1).
RESULTS AND THEIR DISCUSSION
Treatment for Group 1 patients was done using
chronochemotherapy. In this case, one of the schemes
of the treatment standard was selected, and the drugs
were poured into the div in the evening (after
dinner).
In 2 groups of patients, one of the schemes of the
standard of treatment was selected, and drugs were
poured into the div during the day.
All patients after murolaja side effects were studied
based on the general poisoning criterion assessment
table established by the World Health Organization as
a whole (table 2).
2 table.
Side effects observed in patients receiving chemotherapy and chrono chemotherapy and their degree of poisoning
№
Characters
Poisoning rate
0
I
II
III
IV
N
%
n
%
n
%
n
%
n
%
1
Anorexia
I
2
6,4
8
25,8
12
38,7
9
29,1
0
0
II
0
0
5
15,6
7
21,8
18
56,3
2
6,3
2
Nausea
I
0
0
10
27,0
19
51,3
8
21,7
0
0
II
0
0
2
5,3
24
63,2
12
31,5
0
0
3
Vomit
I
0
0
9
60,0
5
33,3
1
6,7
0
0
II
0
0
4
22,2
8
44,4
5
27,8
1
5,6
4
Zarda
I
7
31,8
10
45,5
3
13,6
2
9,1
0
0
II
4
14,4
14
50,0
5
17,8
5
17,8
0
0
Volume 03 Issue 04-2023
133
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
5
Stomatitis
I
1
12,5
6
75,0
1
12,5
0
0
0
0
II
0
0
10
83,4
1
8,3
1
8,3
0
0
6
Taste
disorders
I
11
55,0
7
35,0
2
10,0
0
0
0
0
II
8
36,4
10
45,4
4
18,2
0
0
0
0
7
Diarrhea
I
5
62,5
2
25,0
1
12,5
0
0
0
0
II
5
50,0
3
30,0
2
20,0
0
0
0
0
Group 1 patients experience anorexia at 51.6 %, nausea
at 61.7 %, vomiting at 25 %, dice at 36.6 %, stomatitis at
13.3 %, taste disorders at 33.3%, and diarrhea at 13.3%.
Group 2 patients experience anorexia at 53.3 %, nausea
at 63.3 %, vomiting at 28.3 %, dice at 46.6 %, stomatitis
at 20 %, taste disorders at 36.6%, and constipation at
16.6%.
Table 2 shows that all side effects showed a milder
extent in Group 1 patients compared to Group 2
patients.
CONCLUSION
The result of scientific research showed that patients
undergoing chronochemotherapy treatments had a
lower and milder level of div poisoning of 1.11
marotiba according to traditional chemotherapy.
REFERENCES
1.
Arushanyan E.B., Baturin V.A. Fundamentals of
chronopharmacology, Stavropol, 1989. 67 p.
2.
Bekhtereva I. Ya. Neurophysiological aspects of
mental activity. - L .: Medicine, 1974. - 151 p.
3.
V. GRINEVICH. ilmiy journal “Science and Life”,
2005 yil No. 1 dream.
4.
Valiev O.M., Ismailov Sh.I., 1990. 109 p.
5.
Vasilyeva G. S. Chronobiology and chronotherapy
of malignant neoplasms (experimental clinical
studies): Abstract of the thesis. dis. Dr. Biol.
Sciences. - Almaty, 1994 - 78 p.
6.
Dobrokhotov V.N. et al., Atypical cell morphology.
1964. 111 p.
7.
Efimov M. L. Biological rhythms in norm and
pathology. - Alma-Ata, 1981. - 152 p.
8.
M. L. Efimov, G. S. Vasil’eva, V. R. Kovalenko, et al.,
Vopr. oncology. - 1989. - T. 35, N 9. - S. 1068-1071.
9.
Zaslavskaya
R.
M.
Chronodiagnosis
and
chronotherapy of diseases of the cardiovascular
system.
—
M.: Medicine, 1991.
—
320 p.
10.
Komarov F. I., Zakharov A. V., Lisovskiy V. A. Daily
rhythm of physiological functions in a healthy
person. - L .: Medicine, 1966. - 200 p.
11.
F. I. Komarov and S. I. Rapoport, Klin. medicine. -
1993. - N 5. - S. 4-9.
12.
Komarova F.I., Rapoporta S.I. Chronobiology and
chronomedicine / Ed.
–
2nd ed. - M.: Triada-X, 2000.
- 488 p.
13.
Moiseeva N. I., Sysuev V. M. Temporal environment
and biological rhythms.- L .: Nauka, 1981.- 127 p.
14.
Oransky I. E., Tsarfis P. G. Biorhythmology and
chronotherapy
(chronobiology
and
chronobalneophysiotherapy).
—
M.: Vyssh. shk,
1989.
—
159 p.
Volume 03 Issue 04-2023
134
International Journal of Medical Sciences And Clinical Research
(ISSN
–
2771-2265)
VOLUME
03
ISSUE
04
P
AGES
:
129-134
SJIF
I
MPACT
FACTOR
(2021:
5.
694
)
(2022:
5.
893
)
(2023:
6.
184
)
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
15.
Romanov Yu.A., 2000;
16.
Tabolin V.A. et al., 1969
17.
Ulashchik
V.S.,
biological
rhythms
and
chronotherapy, journal. Medical news. 1996 No. 2.
18.
Chissov V. I., Davydov M. I. Oncology national
leadership. - Moscow, Goetar media, 2014. - 483 p.
19.
Beryozkin M.V., chronopharmacology. 1977, 259 p.
20.
Hrushesky W. // Science. - 1985. - V. 228, N 4695. - P.
73-75.
21.
Oransky I. et al., Science. - 1995. - V. 202, N 1269. - P.
43-46.
